Welcome to our dedicated page for Doximity SEC filings (Ticker: DOCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Doximity filings document financial results, material events, governance actions, and capital-structure details for the operator of a digital platform for U.S. medical professionals. Recent Form 8-K disclosures cover quarterly results and related exhibits, finance and legal leadership changes, Regulation FD updates, and annual-meeting voting outcomes.
The company's regulatory record also includes shareholder voting matters tied to its Class A and Class B common stock structure, director elections, auditor ratification, material agreements, and other security-holder matters. These filings describe how Doximity reports operating performance, governance changes, voting mechanics, and formal public-company events.
Doximity, Inc. (DOCS) Form 144 notifies the market that a person plans to sell 20,000 shares of Common stock through Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $1,275,566.00 and reports 187,299,459 shares outstanding. The shares to be sold were acquired the same day, 08/15/2025, by stock option exercise from the issuer and paid for in cash. The filer also reported two recent sales in the past three months: 10,000 shares sold on 06/25/2025 for $600,000.00 and 10,000 shares sold on 05/23/2025 for $505,796.00. The signer certifies no undisclosed material adverse information.
Doximity, Inc. announced that its General Counsel, Corporate Secretary, and Chief Compliance Officer, Jennifer Chaloemtiarana, will step down from all three roles effective August 29, 2025, and John Vaughan will assume these positions on the same date.
Chaloemtiarana will continue with the company in an advisory capacity through November 17, 2025, after which she will receive post-employment payments and benefits under her August 10, 2020 offer letter referenced in a prior Form 10-Q filing.
Benjamin Regina M., a director of Doximity, Inc. (DOCS), reported transactions dated 08/08/2025. The Form 4 shows the conversion of 5,000 shares of Class B Common Stock into Class A Common Stock and the sale of 5,000 shares of Class A Common Stock at $63 per share. The sale occurred automatically under a Rule 10b5-1 trading plan adopted February 26, 2025.
Following the reported transactions the form lists the Reporting Person's beneficial ownership as 16,618 shares of Class A Common Stock. The filing also discloses derivative/option positions, with one line showing 361,138 derivative-equivalent shares beneficially owned after the reported transactions. The Form 4 is signed by an attorney-in-fact on 08/11/2025.
Form 144 filed for proposed sale of common stock. The notice reports a proposed sale of 5,000 shares through Morgan Stanley Smith Barney on the NYSE with an aggregate market value of $315,000 and states total shares outstanding of 187,299,459. The securities are shown as acquired on 08/08/2025 by a stock option exercise from the issuer and paid in cash.
The filing also discloses prior sales by the same account in the past three months: 5,000 shares sold on 07/11/2025 for $300,200 and 10,000 shares sold on 06/25/2025 for $600,000. The signer attests they have no undisclosed material information as of the notice.